Abstract:Background Systemic sclerosis (SSc) is a chronic inflammatory disease with complex pathogenesis. The role of regulatory T cells (Tregs) in the development of SSc has started being studied during the last decade with new aspects being disclosed continuously. Although there is a general agreement in the medical literature regarding the decreased functional capacity of circulating Tregs in SSc, the alteration of absolute number of Treg cells as well as orther CD4 +T lymphocyte subsets in SSc is still unclear. Objectives The aim of the present study was to explore the absolute number status of CD4 +T subsets in peripheral blood of patients with SSc using our modified flow cryometric method and investigate whether the imbalance of Th17 and Treg cells can be corrected by supplementing low dose interleukin −2 (IL-2). Methods The peripheral CD4 +T subsets from 54 patients with SSc and 30 healthy control subjects were analysed. The patients were divided into the untreated group (n=29) and treated group (n=25). The patients were also divided into group A (n=28) who only used low-dose glucocorticoids (GCS), and group B (n=26) who also used immunosuppressant cyclophosphamide (CYC), methotrexate (MTX), leflunomide (LEF) or mycophenolate mofetil (MMF). In addition, 21 patients from 54 patients, given a small dose of IL-2 (50WIU) treatment for a 5 day course, divided into pre-treatment group and post-treatment group. Directly using the results from flow cytometry combined with internal standard beads, absolute number of peripheral CD4 +T subsets from the subjects in each group were calculated. Results Although there were some changes among CD4 +T cell subsets in peripheral blood from these SSc patients, the major alteration was the reductions of Treg cell absolute number. Compared with the normal controls, the number of CD4+CD25+FOXP3+Treg cells were significantly decreased in all patients (p=0.001), in untreated group (p=0.029), in treated group (p=0.029), in group A (p=0.006) and in group B (p=0.004). The ratio of Th17/Treg in total patients (p=0.008) and group B (p=0.001) were significantly higher than that in normal control group, and the group B was significantly higher than the group A (p=0.032). Moreover, the number of Th17 cells in group B was significantly higher than that in group A (p=0.023). After IL-2 treatment, the absolute number of CD4+CD25+FOXP3+Treg cells (p 0.05). Since Th17 cells increases significantly lower than Treg cells, so their ratio decreases significantly (p=0.001) to get re-balance. Conclusions The absolute number of peripheral CD4 +CD25+FOXP3+Treg cells decreased in untreated patients, indicating that this reduction arising from the disease itself. Our findings suggest that SSc progression is associated with the absolute decrease of peripheral Treg cells. Although there was no statistically significant different, absolute number of the Treg cells trended to decrease in patients treated with immunosuppressive agents. The use of IL-2 can effectively up-regulate Treg cells as well as increase Th17 to a certain extent, which restores the balance of Th17/Treg cells, but the long-term effect needs further investigation. Disclosure of Interest None declared

Jeg-3 human choriocarcinoma-induced immunosuppression: downregulation of interleukin-2, interleukin-2 receptor alpha-chain, and its Jak/Stat signaling pathway

Ovarian Carcinoma Cell Supernatants Inhibit Proliferation and IL-2R Expression of CD8~+ T Cell

Impact of Axis of GHRH and GHRH Receptor on Cell Viability and Apoptosis of the Placental Choriocarcinoma Cell Line.

Ovarian Carcinoma Cells Inhibit T Cell Proliferation: Suppression of IL-2 Receptor Β and Γ Expression and Their JAK-STAT Signaling Pathway

[Ovarian carcinoma cell inhibits T cell JAK-STAT signal transduction pathway, an experimental study].

IL-6 Antisense-Mediated Growth Inhibition of a Choriocarcinoma Cell Line: An Intracellular Autocrine Growth Mechanism

Ovarian caremoma cell supernatants inhibit proliferation and IL-2R expression of CD8+ T cell

miR-22 promotes immunosuppression via activating JAK/STAT3 signaling in cutaneous squamous cell carcinoma

Activation of STAT3 in Human Gastric Cancer Cells Via Interleukin (Il)-6-type Cytokine Signaling Correlates with Clinical Implications

Reduction of Pl-Csa Through ChSy-2 Knockout Inhibits Tumorigenesis and Metastasis of Choriocarcinoma in JEG3 Cells.

THU0412 Absolute reduction of peripheral cd4 + regulatory t cell subset of patients with systemic sclerosis and its restoration by short-term and low dose il-2 treatment

Human Epithelial Ovarian Carcinoma Cell-Derived Cytokines Cooperatively Induce Activated Cd4+Cd25-Cd45ra+Naive T Cells To Express Forkhead Box Protein 3 And Exhibit Suppressive Ability In Vitro

Effects of Interleukin-6 on STAT3-regulated signaling in oral cancer and as a prognosticator of patient survival

Insights into cAMP‐dependent molecular mechanisms regulating expression and function of LGALS16 gene in choriocarcinoma JEG‐3 cells

Anti-CD3antibody-induced Expression Ofbothp55andp75chains Ofthehighaffinity Interleukin-2 Receptor on Humant Lymphocytes Isinhibited Bycyclosporin A

Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome

Heparanase expression correlates with metastatic capability in human choriocarcinoma.

Interleukin-2 (IL-2) receptor-betagamma signalling is activated by c-Kit in the absence of IL-2, or by exogenous IL-2 via JAK3/STAT5 in human papillomavirus-associated cervical cancer

Overexpression Of Hypoxia-Inducible Factor 1 Alpha Induces Migration And Invasion Through Notch Signaling

Human choriogonadotropin (hCG) and placental lactogen (hPL) inhibit interleukin-2 (IL-2) and increase interleukin-1 beta (IL-1 beta), -6 (IL-6) and tumor necrosis factor (TNF-alpha) expression in monocyte cell cultures

IL-6 Upregulates the Expression of IL-6R Through the JAK2/STAT3 Signalling Pathway to Promote Progression of Hepatocellular Carcinoma